PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
0.01%
ROE below 50% of Drug Manufacturers - Specialty & Generic median of 0.71%. Jim Chanos would investigate potential structural issues or mismanagement.
0.01%
ROA below 50% of Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos would investigate if assets are overvalued or underutilized.
-0.30%
Negative ROCE while Drug Manufacturers - Specialty & Generic median is 0.14%. Seth Klarman would investigate whether a turnaround is viable.
70.27%
Gross margin 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 50.73%. Mohnish Pabrai would verify if a unique value chain offers pricing benefits.
-3.13%
Negative operating margin while Drug Manufacturers - Specialty & Generic median is 0.57%. Seth Klarman would look for a path to operational turnaround.
0.14%
Net margin below 50% of Drug Manufacturers - Specialty & Generic median of 2.56%. Jim Chanos would be concerned about structural profitability issues.